A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.

Dr. Sigurd Berven to Highlight NOCISCAN Capabilities, Combining MR Spectroscopy and Augmented Intelligence (AI) NOCISCAN as ...

It was given to people who had acute surgical pain from either abdominoplasty, also known as a tummy tuck, or bunion surgery.

The novel formulation of rizatriptan and meloxicam (Symbravo, Axome Therapeutics) is for the acute treatment of migraine with ...

Supernumerary teeth, or extra teeth, can cause various problems for your dental health. These additional teeth can appear in ...

Read about exa-cel being rolled out on the NHS, providing a 'functional cure' for some patients with severe sickle cell ...

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

The U.S. Food and Drug Administration (FDA) has approved Journavx, a new pain reliever without the risks of addiction ...

Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...

A sip of a smoothie ended in a debilitating illness for 21-year-old Mia Ristaino who is now unable to leave the house because ...

Micha Acopiado has been diagnosed with a stage 3 brain tumour after her partner noticed an odd symptom, as her work friends ...